Share

February 09, 2021; 96 (6) Editorial

Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome

Should There Be More to Come?

Marinos C. Dalakas
First published December 14, 2020, DOI: https://doi.org/10.1212/WNL.0000000000011349
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
127

Share

Article Information

vol. 96 no. 6 239-240
DOI: 
https://doi.org/10.1212/WNL.0000000000011349
PubMed: 
33318165
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 14, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Marinos C. Dalakas, MD
  1. Marinos C. Dalakas, MD
    2. Scientific Advisory Boards:

    1. Serves on the CIDP DSMB for Baxalta and Octapharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Merck/Serono, OCTAPHARMA, PFIZER AG,

    Editorial Boards:

    1. 1. Neurology, editorial board (5 years, not compensated); 2)BMC Neurology (Section Editor, 5 years not compensated); 3) Acta Myologica, editorial board (5 years, not compensated); 5)Acta Neurologica Scandinavica editorial board ( 5 years, not compensated); 6)Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated); 7) Annals of Neurology (3 years not compensated); 8) Neurology, Neuroimmunology Neuroinflammation (Associate Editor, compensated); 9)Neurodiem (Associate editor, compensated)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Therapath, Baxter, Octapharma, Dysimmune Diseases Foundation

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received Institutional support to Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, InfuCare, and Newfactor

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Thomas Jefferson University, Philadelphia, PA; and the Neuroimmunology Unit, National and Kapodistrian University of Athens Medical School, Greece.
  1. Correspondence
    Dr. Dalakas marinos.dalakas{at}jefferson.edu
View Full Text

Article usage

Article usage: December 2020 to April 2022

AbstractFullPdfSource
Dec 20200020Highwire
Jan 2021008Highwire
Feb 20215645747Highwire
Mar 20211241016Highwire
Apr 20215513Highwire
May 20216234Highwire
Jun 202114463Highwire
Jul 202112733Highwire
Aug 20219125Highwire
Sep 20215954Highwire
Oct 20217425Highwire
Nov 20214611Highwire
Dec 20215010Highwire
Jan 20222320Highwire
Feb 20224434Highwire
Mar 20224213Highwire
Apr 20223201Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me